CAR-T Therapies
Specialty Channel

Featured Article
Premal Lulla, MBBS, discusses his team's study on the use of nonengineered T-cells for the treatment of patients with HL and NHL.
The FDA has approved lisocabtagene maraleucel, a new CAR-T therapy, for the treatment of adults with relapsed or refractory large B-cell lymphoma after at least 2 lines of systemic therapy.
True or False: In the KarMMA clinical trial, investigators looked at the use of anti-BCMA CAR-T therapy for relapsed/refractory MM.
RT is an effective bridging option for disease control in high-risk patients with relapsed/refractory LBCL preparing to receive CAR-T therapy.
Fractionated CAR-T Therapy dosing improved _________ in Relapsed/Refractory ALL?
True or False: Radiotherapy can be an effective bridging strategy for disease control in high-risk patients with relapsed/refractory large B-cell lymphoma preparing to receive CAR-T therapy.
True or False: The majority of patients in the phase 2 ZUMA-2 trial with relapsed or refractory MCL benefited from treatment with KTE-X19, an anti-CD19 CAR-T therapy.
_________ is an effective bridging option for disease control in high-risk patients with relapsed or refractory LBCL preparing to receive CAR-T therapy.
True or False: Factors tied to EFS outcomes in patients with B-cell ALL who achieve MRD-negative complete remission after CD19 CAR-T therapy include baseline platelet count, lactate dehydrogenase,…

News

The FDA approved idecabtagene vicleucel for the treatment of patients with multiple myeloma who have not responded to, or whose disease has returned after, at least 4 prior lines of therapy.
The FDA has approved lisocabtagene maraleucel, a new CAR-T therapy, for the treatment of adults with relapsed or refractory large B-cell lymphoma after at least 2 lines of systemic therapy.
RT is an effective bridging option for disease control in high-risk patients with relapsed/refractory LBCL preparing to receive CAR-T therapy.
Results from a follow-up of the phase 2 ZUMA-2 trial revealed that the majority of patients with relapsed or refractory MCL benefited from treatment with KTE-X19.

Interactive Features

True or False: In the KarMMA clinical trial, investigators looked at the use of anti-BCMA CAR-T therapy for relapsed/refractory MM.
Fractionated CAR-T Therapy dosing improved _________ in Relapsed/Refractory ALL?
True or False: Radiotherapy can be an effective bridging strategy for disease control in high-risk patients with relapsed/refractory large B-cell lymphoma preparing to receive CAR-T therapy.
True or False: The majority of patients in the phase 2 ZUMA-2 trial with relapsed or refractory MCL benefited from treatment with KTE-X19, an anti-CD19 CAR-T therapy.
Stay in the know.
OncNet Newsletter